Oppenheimer Reiterates Outperform Rating on UroGen Pharma (URGN) "We Buy the Weakness"
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $31.00 price target on UroGen Pharma (NASDAQ: URGN)The analyst commented, "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
